Search Results
Jun 09, 2026, 11:46 ET /C O R R E C T I O N -- Mews/
Wette aus.„Das Gastgewerbe orientiert sich seit Jahrzehnten an einer Kategorisierung, die vor 40 Jahren entworfen wurde. PMS, RMS, CRS, CRM und POS sind einfach Abkürzungen, die von Softwarefirmen erfunden wurden, um mehr Software zu verkaufen. Auf Mews gibt es diese Kategorien nicht
More news about: Mews
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller
More news about: AbbVie
Jun 08, 2026, 05:01 ET Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress
clear trend of lower inflammatory cytokine release compared to glofitamab, successfully mitigating the primary driver of Cytokine Release Syndrome (CRS).In Vivo Tumor Clearance: In humanized NOG mouse models, KT209 achieved potent, dose-dependent anti-leukemia activity.Favorable
More news about: Kali Therapeutics
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
second-line agents, heralding a potential new era of long-term survival for patients with advanced HCCSafety: Cytokine release syndrome (CRS) was manageable; no immune effector cell-associated neurotoxicity syndrome (ICANS) or off-target toxicity was observed, and tolerability was favourable
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Jun 04, 2026, 17:31 ET The Inner Circle acknowledges Wynne Achatz as a Pinnacle Professional Member Inner Circle of Excellence
assisted living options. Her dedication to client service is supported by an impressive set of professional designations, including SFR, RAM, SRES, GRI, CRS, ABR, and C2EX, underscoring her commitment to professional development and industry expertise.Wynne' achievements have been recognized through
More news about: The Inner Circle
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with ZYNLONTA plus rituximab. Overall, treatment emergent adverse event (TEAE) rates were similar between arms. Similar rates of
More news about: ADC Therapeutics SA
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
Patienten nach der zweiten Dosis CRS jeglichen Grades erlebten. Die Mehrheit der CRS-Ereignisse trat nach den ersten beiden Dosen auf, wobei 8,5 % der Patienten nach der dritten Dosis oder später ein CRS erlebten. Nach der Infusion am Tag 1 traten bei 13,7 % der Patienten CRS ≥ Grad 2 auf. Nach der Infusion
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
dávke u 34,0 % pacientov. Väčšina príhod CRS sa vyskytla po prvých dvoch dávkach, u 8,5 % pacientov sa CRS vyskytol po tretej alebo ďalšej dávke. Po infúzii v 1. deň sa u 13,7 % pacientov vyskytol CRS ≥ 2. stupňa. Po infúzii v 8. deň sa u 4,4 % pacientov vyskytol CRS ≥ 2. stupňa. Medián času od podania poslednej
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
po druhé dávce se CRS libovolného stupně vyskytl u 34,0 % pacientů. Většina příhod CRS se vyskytla po prvních dvou dávkách, přičemž u 8,5 % pacientů se CRS vyskytl po třetí dávce nebo později. Po infuzi v 1. dni se CRS ≥ 2. stupně vyskytl u 13,7 % pacientů. Po infuzi v 8. dni se CRS ≥ 2. stupně vyskytl
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
4 u 0,2% pacjentów. Nawracający CRS wystąpił u 24% pacjentów leczonych preparatem IMDELLTRA®, w tym: u 20%: stopień 1, u 3,4% stopień 2, u jednego pacjenta nawracający CRS stopnia 3.Wśród 268 pacjentów, u których wystąpił CRS: u 73% CRS wystąpił po pierwszej dawce, u 60%
More news about: Amgen
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
явления CRS были зарегистрированы у 19,7% пациентов. После первой дозы IMDYLLTRA 41,4% пациентов испытывали любую степень CRS, при этом 34,0% пациентов испытывали любую степень CRS после второй дозы. Большинство явлений CRS произошло после первых двух доз, при этом 8,5% пациентов испытывали CRS после третьей
More news about: Amgen
Jun 03, 2026, 00:00 ET Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Jun 02, 2026, 08:00 ET The Rise of the American Drone Industry
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Jun 02, 2026, 07:01 ET Cowbell Named to Inc.'s 2026 Best Workplaces List
in commercial and specialty lines, including cyber, technology errors and omissions, and management liability. Through Cowbell Resiliency Services (CRS)—an independent cybersecurity advisory arm—policyholders gain access to Digital Forensics and Incident Response (DFIR) services as well as proactive solutions
More news about: Cowbell Cyber, Inc.
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
of CRS were reported in 19.7% of patients. After the first dose of IMDYLLTRA, 41.4% of patients experienced any grade CRS, with 34.0% of patients experiencing any grade CRS after the second dose. The majority of CRS events occurred after the first two doses, with 8.5% of patients experiencing CRS following
More news about: Amgen
May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
was manageable: No immune effector cell-associated neurotoxicity syndrome (ICANS) or off-tumor toxicity was observed, with cytokine release syndrome (CRS) contained within controllable grades.Long-Term Validation: From 2021 ASCO Poster to Registrational DataNotably, as early
More news about: Oricell Therapeutics Holdings Limited
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
patients remained alive, with follow-up durations of 58.1 months and 51.1 months.As for safety, no grade 3 or higher cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade, and no treatment-related deaths occurred. No grade ≥3 infections or
More news about: CARsgen Therapeutics
May 29, 2026, 09:19 ET PeproMene Bio kündigt Vortrag auf der EHA 2026 an, der günstiges Sicherheitsprofil und dauerhaftes Ansprechen mit PMB-CT01 (BAFF-R-CAR-T-Zelltherapie) bei B-Zell-Lymphomen hervorhebt, auch nach vorherigem Versagen einer CD19-CAR-T-Zelltherapie
Phase behandelt wurden, zeigte PMB-CT01 ein vielversprechendes Sicherheitsprofil ohne dosisbegrenzende Toxizitäten, ohne Zytokinfreisetzungssyndrom (CRS) von Grad > 1 sowie ohne Immuneffektorzell-assoziiertes Neurotoxizitätssyndrom (ICANS) von Grad > 1. Sieben von neun Patienten (78 %) erreichten
More news about: PeproMene Bio, Inc.
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity.
More news about: Johnson & Johnson
May 29, 2026, 08:15 ET PeproMene Bio annonce une présentation orale à l'EHA 2026 mettant en évidence un profil de sécurité favorable et des réponses durables avec la PMB-CT01 (thérapie CAR-T anti-BAFF-R) dans les lymphomes à cellules B, y compris après l'échec d'une thérapie CAR-T CD19 antérieure
cours de cette phase, la PMB-CT01 a démontré un profil de sécurité prometteur, sans toxicité limitant la dose, sans syndrome de libération de cytokines (CRS) de grade > 1 et sans syndrome de neurotoxicité associée aux cellules effectrices immunitaires (ICANS) de grade > 1. Sept patients sur neuf (78 %)
More news about: PeproMene Bio, Inc.
May 29, 2026, 07:35 ET Arkade Developers Reports Robust FY26 Growth; Filmistan Acquisition To Drive Next Phase Of Value Creation
visibility. Furthermore, Arkade Developers has recently secured cluster redevelopment rights for 9 Societies at Kandivali E with a projected GDV of appx 1,100 Crs spanning across 3 Acres.During FY26, Arkade Developers completed the strategic acquisition of Filmistan Private Limited and related ownership
More news about: Arkade Developers Limited
May 29, 2026, 00:55 ET 페프로민 바이오, 이전 CD19 CAR T세포 치료 실패 후를 포함한 B세포 림프종에서 PMB-CT01(BAFF-R CAR T세포 치료제)의 우수한 안전성과 지속적인 반응을 강조하는 EHA 2026 구두 발표 예고
NCT05370430).이 단계에서 치료를 받은 9명의 환자 가운데 PMB-CT01은 용량 제한 독성 없이, 1등급 초과 사이토카인 방출 증후군(cytokine release syndrome, CRS) 및 1등급 초과 면역효과세포 관련 신경독성 증후군(immune effector cell-associated neurotoxicity syndrome, ICANS) 없이 유망한 안전성 프로파일을 보였다. 9명 중 7명(78%)이 완전 반응(complete response,
More news about: PeproMene Bio, Inc.
May 28, 2026, 07:00 ET PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure
treated in this phase, PMB-CT01 demonstrated a promising safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome (CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR).
More news about: PeproMene Bio, Inc.